PacRim7 7th PacRim Meeting Poster Presentations (1) (52 abstracts)
Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer
Heloisa Helena Milioli 1, , Kee Ming Chia 1, , Neil Portman 1, , Aliza Yong 1, , Gerald Tarulli 3 , Luke Selth 3 , Wayne Tilley 3, , Theresa Hickey 3, & Elgene Lim 1,
1Garvan Institute of Medical Research, Sydney NSW Australia; 2St Vincent’s Clinical School, University of New South Wales, Sydney NSW Australia; 3Dame Roma Mitchell Cancer Research Laboratories, The University of Adelaide, Adelaide SA Australia. *These authors contributed equally to the work.
Steroid hormone receptors (SHR) play a major role in the normal breast development and breast cancer progression. Estrogen receptor (ER) is expressed in approximately 75% of breast cancers, and the majority of these tumours also express the androgen receptor (AR). While ER-directed therapies have been effective in the majority of patients, a significant subset develops resistance and requires alternative treatment approaches. In the endocrine-resistant setting, emerging insights into the role of androgen signalling have revived interest in AR-targeted therapies for novel pre-clinical studies and clinical trials. An understanding of AR activation in this setting is critical to improve the rational design of trials involving AR-directed therapies. In this study, we sought to characterize the AR downstream signalling pathway and assess the efficacy of AR-targeted agents in endocrine-resistant cell lines and patient-derived xenografts (PDXs) models. We performed RNA-Seq and ChIP-Seq analyses to interrogate the SHR dynamic at the genomic, transcriptomic and proteomic levels. Transcriptional profiling of AR-targeted tumours revealed gene signatures (~200 genes) associated with ER-regulated genes repertoire that predicts for better disease outcome (pval=6e-10) in ER-positive breast cancer patients across METABRIC and ROCK public cohorts. AR agonists DHT and enobosarm (selective AR modulator) inhibited in vitro and in vitro tumour growth of endocrine-resistant MCF7 cells and two PDXs (Gar15-13 and HCI005) and demonstrated anti-proliferative (Hallmarks of G2M-checkpoint and E2F-targets) and anti-estrogenic (ER-targets) effects. These findings validate the utility of AR agonists in the treatment of endocrine-resistant ER-positive breast cancer, and further support the identification of biomarkers for novel AR-directed therapies and subsequent clinical trials.
Article tools
My recent searches
My recently viewed abstracts
Authors
Oncology Abstracts
ISSN 2631-4657 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more